Eli Lilly, drugmakers present data on weight-loss drugs | Wilnesh News

Do you think a friend or colleague should receive this newsletter? share this link Sign up with them.

good morning! Eli Lilly and Company, Novo Nordisk and other drugmakers last week presented encouraging data on weight loss and diabetes drugs.

Companies share results with American Diabetes Association Annual Meeting The world’s largest scientific conference focused on diabetes research, prevention and care, held in Orlando, Florida.

The drugs are being developed amid growing investor interest in treatments for metabolic diseases, particularly a popular class of drugs called GLP-1

But drug companies are proposing treatments that differ from traditional GLP-1, such as Novo Nordisk’s popular weight-loss injection Wegovy and its diabetes counterpart Ozempic. These two drugs mimic hormones produced in the gut to suppress a person’s appetite.

Companies are also no longer focused solely on weight loss in trials. Some drugmakers are studying the potential of their drugs to treat other health conditions, while others are studying whether the drugs can preserve patients’ lean muscle mass while promoting weight loss.

Here are some highlights from the conference:

• Eli Lilly and Company Additional data released from two late-stage clinical trials showed that its weight-loss injection Zepbound helped address a common sleep disorder called obstructive sleep apnea in nearly half of patients. Zepbound could receive expanded U.S. approval for that use as soon as the end of this year, the company said.
• Novo Nordisk Key clinical trial results of semaglutide (the active ingredient in Wegovy and Ozempic) in diabetes, obesity, and chronic kidney disease are presented. Included are full results from Ozempic’s late-stage trials in patients with diabetes and chronic kidney disease. Weekly injections significantly reduced patients’ risk of progression of kidney disease and death from renal or cardiovascular complications. new data The benefits were also shown to be consistent whether or not patients were also treated with a class of diabetes drugs called sodium-glucose cotransporter 2 inhibitors. Novo Nordisk expects U.S. regulators to make a decision on approval to expand this use in January 2025.
• new zealand pharmaceutical company Early clinical trials of its experimental weekly injection of petrelintide, which targets the hormone amylin, have shown positive results. The drug resulted in an 8.6% weight loss at 16 weeks, compared with a 1.7% weight loss in patients taking a placebo. The Danish company sees the drug as a weight-loss alternative to GLP-1.
• Al immune freed complete data from mid-stage clinical trials of its experimental obesity drug pemvidutide. The treatment preserves lean muscle mass while promoting weight loss in obese adults, with most of the loss coming from fat. A subgroup analysis of 50 patients found that only 21.9% of their weight loss came from lean muscle mass.
• Viking therapy Revealed preclinical data A series of experimental drugs called dual amylin and calcitonin receptor agonists (DACRA). Results showed that the company’s DACRA reduced the amount of food the mice ate during the first three days after a single dose. After three days of taking the drug, the mice lost 8% more weight than mice receiving Novo Nordisk’s experimental weight loss drug CagriSema.
• Gilead present data From a preclinical study of an experimental oral GLP-1 called GS-4571. The trial found that the treatment improved glucose tolerance in mice and led to a 5% to 6% weight loss within five days, according to a note from analysts at Jefferies on Sunday. The note cited a poster at the conference, adding that obese monkeys lost 8% of their body weight after 30 days.

Please feel free to send Annika any tips, suggestions, story ideas and data: annikakim.constantino@nbcuni.com.

Oracle On Monday, the company expanded access to its artificial intelligence-driven tool called Oracle Clinical Digital Assistant, which is designed to save doctors time by automating some documents.

Oracle says Its clinical digital assistant can help alleviate this administrative burden. Doctors can access the tool through an app on their phone and record patient visits with the push of a button. Once recording is stopped, Oracle’s artificial intelligence automatically generates clinical notes based on the appointment so doctors can No more writing it yourself.

Oracle said only approved representatives of the healthcare organization will have access to the records.

The assistant works with Oracle’s electronic health records, so doctors can also verbally ask it to pull information about a patient’s medical history, such as their latest blood test results, the company said. In other words, doctors can spend less time searching records to find the relevant information they need.

Oracle has tested the tool with 13 healthcare organizations, including Hudson Physicians. Oracle says its assistant saves clinicians an average of four and a half minutes per patient and 20 to 40 percent of daily documentation time. Starting Monday, the tool will generally be available at mobile clinics or clinics not affiliated with a hospital.

“This is going to be a practical requirement for our business going forward,” McFarlane said. “The accuracy of notes is much better and you can capture things you might have forgotten to record. This saves time significantly.”

McFarland said he has used other dictation tools in the past, but the software often had bugs and struggled with fast speech. He also works with more accurate human scribes, although he says their training can be time-consuming and it can be difficult to keep a job. McFarland said Oracle Assistant behaves like a human writer.

“I think it’s 90 to 100 percent there from a note generation perspective,” he said.

McFarland said he thinks the tool handles complex medical terminology well and can even capture abbreviations. He said he thinks there’s room for improvement in some specialty care and how assistants help with other functions, such as placing orders for imaging, sending referrals and return-to-clinic reminders.

Some of Dr. Hudson’s providers are more focused on their note-taking style than others, so McFarland said some doctors still spend time editing. Even so, the clinic’s adoption rate for Oracle Assistant has reached 100 percent, something McFarland says he’s never seen before.

“This is a game changer for us and we will continue to use it,” he said.

Please feel free to send any tips, suggestions, story ideas and data to Ashley at ashley.capoot@nbcuni.com.